Individual participant data meta-analysis of 39 phase 2 and 3 trials (20,806 participants) with advanced solid tumours: female sex was associated with better overall survival (HR 0.79) and PFS (HR 0.84) but more grade 3 or higher adverse events (HR 1.12).
Meta-analysisn = 20,806
Chhetri et al. Sex-based prognosis in industry-sponsored advanced solid tumor trials: an individual participant data meta-analysis of survival and adverse events